Identification of an inhibitor of iRhom1 or an inhibitor of iRhom2

US10024844B2 · kind B2 · utility

Assignees

• Hospital for Special Surgery · US
• UNIVERSITY HEALTH NETWORK · CA

Inventors

• Carl Blobel · New York, US
• Thorsten Maretzky · New York, US
• David McIlwain · Toronto, CA
• Tak W. Mak · Toronto, CA

Key dates

• Filing date: Dec 20, 2013
• Grant date: Jul 17, 2018
• Expiry date: Dec 20, 2033

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2500/02
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed are methods for treating a subject with an EGFR dependent pathology. The method comprises the step of administering to the subject an effective amount of an agent (“First Agent”) that decreases the biological activity of iRhom1 and an effective amount of an agent (“Second Agent”) that decreases the biological activity of iRhom2. Alternatively, the method comprises the step of administering to the subject an effective amount of an agent (“First Agent”) that modulates formation of a complex between iRhom 1 and TACE and an effective amount of an agent (“Second Agent”) that modulates formation of a complex between TACE and iRhom2. Also disclosed are assays for identifying such agents.